Surge in Options Trading Volume for GameStop and MicroStrategy
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy SLNO?
Source: NASDAQ.COM
- GameStop Options Volume: GameStop Corp saw options trading volume of 80,627 contracts, equivalent to approximately 8.1 million shares, representing about 139% of its average daily trading volume of 5.8 million shares over the past month, indicating strong market interest.
- High Strike Demand: Notably, the $23.50 strike call option expiring on April 10, 2026, has seen 6,715 contracts traded today, representing around 671,500 underlying shares, suggesting investor expectations for future price increases.
- MicroStrategy Options Volume: Concurrently, MicroStrategy Inc recorded options trading volume of 236,549 contracts, translating to approximately 23.7 million shares, or about 121.4% of its average daily trading volume of 19.5 million shares, highlighting active trading in this stock.
- Strike Price Focus: For the $130 strike call option expiring on April 10, 2026, 8,705 contracts have been traded today, representing approximately 870,500 underlying shares, reflecting optimistic sentiment regarding MicroStrategy's future performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SLNO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SLNO
Wall Street analysts forecast SLNO stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 52.350
Low
75.00
Averages
110.50
High
125.00
Current: 52.350
Low
75.00
Averages
110.50
High
125.00
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Soleno Therapeutics Faces Class Action Lawsuit Over Safety Concerns
- Class Action Initiation: Soleno Therapeutics is facing a class action lawsuit for failing to disclose safety concerns related to its DCCR drug between March 26 and November 4, 2025, which could lead to significant investor losses and damage the company's reputation and market trust.
- Safety Issues Exposed: The lawsuit alleges that Soleno concealed critical safety issues during DCCR's clinical trials, including fluid retention in participants, which poses greater safety risks than disclosed, potentially undermining the drug's commercial viability.
- Stock Price Volatility: Following a negative report from Scorpion Capital in August 2025, Soleno's stock price dropped nearly 12% over two days, and news of a patient death linked to DCCR caused a further 19% decline in September, indicating a severe loss of market confidence in the company's product.
- Legal Consequences and Investor Rights: The class action lawsuit may result in substantial financial liabilities for Soleno, with investors able to seek lead plaintiff status to represent other shareholders, further impacting the company's financial health and strategic direction.
See More
Soleno Therapeutics Faces Securities Fraud Lawsuit
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against Soleno Therapeutics on behalf of investors who purchased common stock between March 26 and November 4, 2025, highlighting serious concerns over the company's financial transparency.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety issues related to its DCCR drug during Phase 3 clinical trials, including fluid retention problems in participants, leading to investor skepticism about the drug's commercial viability.
- Stock Price Plunge: Following the release of financial results on November 4, 2025, Soleno's stock price dropped over 26% due to negative revelations regarding DCCR's launch, indicating a pessimistic outlook from the market on the company's future prospects.
- Investor Action: Investors are encouraged to apply for lead plaintiff status by May 5, 2026, to represent all affected investors, reflecting a crisis of trust in Soleno's management and an urgent need for legal recourse.
See More
Multiple Companies Face Class Action Lawsuits
- Boston Scientific Lawsuit: Boston Scientific faces a class action for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, leading to misleading investor perceptions about its future prospects, with a lead plaintiff deadline of May 4, 2026, potentially undermining shareholder confidence.
- Eos Energy Lawsuit: Eos Energy is accused in a class action of failing to achieve necessary production ramp-up and experiencing excessive battery line downtime beyond industry norms, with a lead plaintiff deadline of May 5, 2026, which could negatively impact its market share.
- Soleno Therapeutics Lawsuit: Soleno is facing a class action for concealing safety issues in its DCCR clinical trial, with a lead plaintiff deadline of May 5, 2026, which may raise concerns about the commercial viability of its product.
- Nektar Therapeutics Lawsuit: Nektar is being sued for not adhering to applicable standards in its REZOLVE-AA trial, with a lead plaintiff deadline of May 5, 2026, which could affect the trial's results and the company's reputation.
See More
Class Action Lawsuit Filed Against Soleno Therapeutics for Securities Fraud
- Lawsuit Background: Kahn Swick & Foti has initiated a class action lawsuit against Soleno Therapeutics, alleging that the company failed to disclose critical information between March 26 and November 4, 2025, resulting in investor losses and highlighting serious transparency issues within the firm.
- Allegation Details: The complaint asserts that Soleno and certain executives systematically minimized and mischaracterized safety concerns related to the DCCR clinical trial, including indications of excessive fluid retention among participants, indicating significant safety risks that were not disclosed to investors.
- Business Impact: The undisclosed safety risks have severely undermined DCCR's commercial viability, potentially leading to increased patient discontinuation rates, reduced prescriber willingness, and significant legal and reputational fallout, exacerbating investor concerns about the company's future.
- Investor Action: Affected investors must request to be appointed as lead plaintiffs by May 5, 2026, although serving as a lead plaintiff is not a prerequisite for recovery, which may prompt more investors to take action to safeguard their interests.
See More
Class Action Lawsuit Filed Against Soleno Therapeutics
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Soleno Therapeutics, alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by May 5, 2026.
- Stock Price Volatility: Following a report from Scorpion Capital on August 15, 2025, labeling Soleno's sole product DCCR as overpriced and potentially unsafe for children, the stock price fell by 7.41%, closing at $71.63, indicating significant market concern.
- Patient Death Incident: On September 10, 2025, Soleno disclosed a patient death linked to DCCR, causing the stock to drop 19.21% over the next two trading sessions to $56.72, highlighting serious safety concerns surrounding the product.
- Adverse Reaction Disclosure: During a quarterly earnings call on November 4, 2025, Soleno revealed an 8% discontinuation rate for DCCR due to adverse effects, with the CEO noting that the Scorpion report disrupted the product's launch trajectory, leading to a 26.59% stock price decline to $46.87, reflecting further erosion of investor confidence.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating Soleno Therapeutics, Inc. (NASDAQ: SLNO) regarding its sale to Neurocrine Biosciences for $53.00 per share, as potential violations of shareholder rights may exist, prompting investors to be aware of their rights and options.
- Acquisition Deal Scrutiny: Forian Inc. (NASDAQ: FORA) is being acquired by a consortium of investors for $2.17 per share, and Halper Sadeh LLC advises shareholders to pay attention to their legal rights to ensure transparency and fairness in the transaction.
- Merger Transaction Impact: The merger between McCormick & Company, Incorporated (NYSE: MKC) and Unilever’s Foods business will result in McCormick shareholders owning 35.0% of the combined entity, with Halper Sadeh LLC potentially seeking increased compensation and disclosures for shareholders.
- Shareholder Rights Protection: Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) is merging with Korsana Biosciences, which is expected to give Cyclerion shareholders approximately 1.5% ownership in the combined company, and Halper Sadeh LLC will represent shareholders in seeking legal remedies and rights protection.
See More
Soleno Therapeutics Faces Class Action Lawsuit Over Safety Concerns
- Class Action Initiation: Soleno Therapeutics is facing a class action lawsuit for failing to disclose safety concerns related to its DCCR drug between March 26 and November 4, 2025, which could lead to significant investor losses and damage the company's reputation and market trust.
- Safety Issues Exposed: The lawsuit alleges that Soleno concealed critical safety issues during DCCR's clinical trials, including fluid retention in participants, which poses greater safety risks than disclosed, potentially undermining the drug's commercial viability.
- Stock Price Volatility: Following a negative report from Scorpion Capital in August 2025, Soleno's stock price dropped nearly 12% over two days, and news of a patient death linked to DCCR caused a further 19% decline in September, indicating a severe loss of market confidence in the company's product.
- Legal Consequences and Investor Rights: The class action lawsuit may result in substantial financial liabilities for Soleno, with investors able to seek lead plaintiff status to represent other shareholders, further impacting the company's financial health and strategic direction.
See More
Soleno Therapeutics Faces Securities Fraud Lawsuit
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against Soleno Therapeutics on behalf of investors who purchased common stock between March 26 and November 4, 2025, highlighting serious concerns over the company's financial transparency.
- Safety Concerns Disclosure: The lawsuit alleges that Soleno concealed significant safety issues related to its DCCR drug during Phase 3 clinical trials, including fluid retention problems in participants, leading to investor skepticism about the drug's commercial viability.
- Stock Price Plunge: Following the release of financial results on November 4, 2025, Soleno's stock price dropped over 26% due to negative revelations regarding DCCR's launch, indicating a pessimistic outlook from the market on the company's future prospects.
- Investor Action: Investors are encouraged to apply for lead plaintiff status by May 5, 2026, to represent all affected investors, reflecting a crisis of trust in Soleno's management and an urgent need for legal recourse.
See More
Multiple Companies Face Class Action Lawsuits
- Boston Scientific Lawsuit: Boston Scientific faces a class action for failing to disclose that its U.S. electrophysiology segment's growth rate was unsustainable, leading to misleading investor perceptions about its future prospects, with a lead plaintiff deadline of May 4, 2026, potentially undermining shareholder confidence.
- Eos Energy Lawsuit: Eos Energy is accused in a class action of failing to achieve necessary production ramp-up and experiencing excessive battery line downtime beyond industry norms, with a lead plaintiff deadline of May 5, 2026, which could negatively impact its market share.
- Soleno Therapeutics Lawsuit: Soleno is facing a class action for concealing safety issues in its DCCR clinical trial, with a lead plaintiff deadline of May 5, 2026, which may raise concerns about the commercial viability of its product.
- Nektar Therapeutics Lawsuit: Nektar is being sued for not adhering to applicable standards in its REZOLVE-AA trial, with a lead plaintiff deadline of May 5, 2026, which could affect the trial's results and the company's reputation.
See More
Class Action Lawsuit Filed Against Soleno Therapeutics for Securities Fraud
- Lawsuit Background: Kahn Swick & Foti has initiated a class action lawsuit against Soleno Therapeutics, alleging that the company failed to disclose critical information between March 26 and November 4, 2025, resulting in investor losses and highlighting serious transparency issues within the firm.
- Allegation Details: The complaint asserts that Soleno and certain executives systematically minimized and mischaracterized safety concerns related to the DCCR clinical trial, including indications of excessive fluid retention among participants, indicating significant safety risks that were not disclosed to investors.
- Business Impact: The undisclosed safety risks have severely undermined DCCR's commercial viability, potentially leading to increased patient discontinuation rates, reduced prescriber willingness, and significant legal and reputational fallout, exacerbating investor concerns about the company's future.
- Investor Action: Affected investors must request to be appointed as lead plaintiffs by May 5, 2026, although serving as a lead plaintiff is not a prerequisite for recovery, which may prompt more investors to take action to safeguard their interests.
See More
Class Action Lawsuit Filed Against Soleno Therapeutics
- Class Action Initiation: Pomerantz LLP has announced a class action lawsuit against Soleno Therapeutics, alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by May 5, 2026.
- Stock Price Volatility: Following a report from Scorpion Capital on August 15, 2025, labeling Soleno's sole product DCCR as overpriced and potentially unsafe for children, the stock price fell by 7.41%, closing at $71.63, indicating significant market concern.
- Patient Death Incident: On September 10, 2025, Soleno disclosed a patient death linked to DCCR, causing the stock to drop 19.21% over the next two trading sessions to $56.72, highlighting serious safety concerns surrounding the product.
- Adverse Reaction Disclosure: During a quarterly earnings call on November 4, 2025, Soleno revealed an 8% discontinuation rate for DCCR due to adverse effects, with the CEO noting that the Scorpion report disrupted the product's launch trajectory, leading to a 26.59% stock price decline to $46.87, reflecting further erosion of investor confidence.
See More
Investor Rights Law Firm Investigates Multiple Companies for Potential Violations
- Legal Investigation Launched: Halper Sadeh LLC is investigating Soleno Therapeutics, Inc. (NASDAQ: SLNO) regarding its sale to Neurocrine Biosciences for $53.00 per share, as potential violations of shareholder rights may exist, prompting investors to be aware of their rights and options.
- Acquisition Deal Scrutiny: Forian Inc. (NASDAQ: FORA) is being acquired by a consortium of investors for $2.17 per share, and Halper Sadeh LLC advises shareholders to pay attention to their legal rights to ensure transparency and fairness in the transaction.
- Merger Transaction Impact: The merger between McCormick & Company, Incorporated (NYSE: MKC) and Unilever’s Foods business will result in McCormick shareholders owning 35.0% of the combined entity, with Halper Sadeh LLC potentially seeking increased compensation and disclosures for shareholders.
- Shareholder Rights Protection: Cyclerion Therapeutics, Inc. (NASDAQ: CYCN) is merging with Korsana Biosciences, which is expected to give Cyclerion shareholders approximately 1.5% ownership in the combined company, and Halper Sadeh LLC will represent shareholders in seeking legal remedies and rights protection.
See More
